ESMO: AstraZeneca's Tagrisso bests rivals at holding off EGFR lung cancer growth

8th September 2017 Uncategorised 0

Right now, AstraZeneca’s Tagrisso is approved to treat only a select group of EGFR-positive lung cancer patients who’ve already taken other EGFR meds. But new data rolled out over the weekend could help change that.

More: ESMO: AstraZeneca's Tagrisso bests rivals at holding off EGFR lung cancer growth
Source: fierce